The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- Acronyms REBBeCA-II
- 06 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
- 06 Oct 2013 Primary endpoint 'Lumbar-spine-bone-mineral-density' has been met.
- 06 Oct 2013 Primary endpoint 'Hip-bone-mineral-density' has been met.